Therapeutic landscape and future direction of metastatic colorectal cancer

Area of Science:

• Oncology
• Genomics
• Cancer Therapeutics

Background:

• The treatment landscape for metastatic colorectal cancer (mCRC) is rapidly evolving, driven by advances in targeted therapies based on specific genomic alterations.
• Genomic profiling, including KRAS, NRAS, BRAF^V600E, ERBB2 status, and mismatch repair (MMR) deficiency, is now recommended before initiating systemic treatment for mCRC.
• Established therapies exist for specific molecular subtypes, such as pembrolizumab for deficient MMR and BRAF^V600E mCRC, and encorafenib/cetuximab combinations.

Purpose of the Study:

• To review the current treatment strategies for metastatic colorectal cancer, focusing on the impact of genomic alterations.
• To highlight the development of new agents targeting rare molecular subtypes within mCRC.
• To discuss the potential of real-world evidence and molecular registries in advancing clinical development for rare genomic alterations.

Main Methods:

• Review of current literature and clinical trial data on targeted therapies in mCRC.
• Analysis of treatment guidelines and recommendations based on tumor genomic status.
• Examination of the role of real-world evidence and molecular registries in drug development.

Main Results:

• Targeted therapies are increasingly important for specific molecular subtypes of mCRC, including ERBB2 alterations and KRAS^G12C mutations.
• The approval of pertuzumab and trastuzumab for ERBB2-positive mCRC in Japan exemplifies progress in treating rare molecular fractions.
• Tumor-agnostic approaches, like those for NTRK fusions, have successfully integrated new drugs into clinical practice.
• Real-world evidence from molecular registries offers a promising solution for clinical trials in rare and fragmented patient populations.

Conclusions:

• Genomic profiling is essential for personalized treatment strategies in mCRC.
• Ongoing development of novel agents and treatment approaches is addressing rare molecular alterations in mCRC.
• Real-world evidence from molecular registries is vital for overcoming challenges in clinical trial design and drug development for rare genomic subtypes of mCRC.